Aluminum and other metals in Alzheimer's disease: a review of potential therapy with chelating agents

  • Domingo J
  • 2


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Alzheimer's disease (AD) is characterized by the presence of neuritic plaques and neurofibrillary tangles in the brain. Although the causes of AD remain still unknown, it seems that certain environmental factors may be involved in the etiology and pathogenesis of the disease. While AD is associated with the abnormal aggregation of beta-amyloid protein in the brain, evidence shows that certain metals play a role in the precipitation and cytotoxicity of this protein. Among these metals, the potential role of aluminum as a possible ethiopathogenic factor in AD has been especially controversial. This review is mainly focused on the role of aluminum and metals such as copper and zinc in AD, as well as on metal chelator therapy as a potential treatment for AD. The effects of desferrioxamine and other Al chelating agents have been reviewed. The role of the metal chelator clioquinol in AD, which has been reported to reduce beta-amyloid plaques, presumably by chelation associated with copper and zinc, is also revised. Finally, the potential role of silicon in AD is also discussed.

Author-supplied keywords

  • Aluminum/*metabolism
  • Alzheimer Disease/*drug therapy/*metabolism
  • Chelating Agents/*therapeutic use
  • Clioquinol/*therapeutic use
  • Copper/*metabolism
  • Humans
  • Mercury/*metabolism
  • Zinc/*metabolism

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • J L Domingo

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free